GA Gene Therapy Interest Increases - Summary - MDSpire
Clinical Guidelines

GA Gene Therapy Interest Increases

Phase I trial results of PulseSight Therapeutics’ PST-611 to be presented at ARVO 2026

  • May 1, 2026

  • 2 min

Share

PulseSight Therapeutics has announced the completion of the last patient, last visit in its phase 1 trial of PST-611, a novel non-viral gene therapy for geographic atrophy associated with dry age-related macular degeneration. The trial, conducted in Paris and Grenoble, evaluated the safety and tolerability of PST-611 in six patients. Results will be presented at the ARVO 2026 meeting by Professor Francine Behar-Cohen, marking a critical step towards the next phase of development. PST-611 targets dysregulated iron homeostasis, potentially preserving visual function and offering a less invasive treatment option.

Original Source(s)

GA Gene Therapy Interest Increases

  • May 1, 2026

Related Content

Ocugen GA Trial Advances Toward Phase 3

Ocugen reports positive Phase 2 data for its OCU410 gene therapy in geographic atrophy

  • May 1, 2026

  • 3 min
TULIP: A New Approach to IOP Reduction

Low-power ultrasound biomodulation may offer a noninvasive, repeatable strategy to lower IOP without tissue destruction.

Emerging Technologies in Continuous IOP Monitoring

Wearable and implantable devices offer new data on pressure variability, though barriers to routine use persist.